Sustained benefits of imetelstat on patient-reported fatigue in patients with lower-risk myelodysplastic syndromes ineligible for, or relapsed/refractory to, erythropoiesis-stimulating agents and high transfusion burden in the phase 3 IMerge study. - Sekeres, Mikkael A.; Santini, Valeria; Díez-Campelo, Maria; Komrokji, Rami S.; Fenaux, Pierre; Savona, Michael R.; Madanat, Yazan F.; Valcárcel-Ferreiras, David; Oliva, Esther Natalie; Regnault, Antoine; Creel, Kristin; Sengupta, Nishan; et al. (Leukemia & Lymphoma, 2025)